Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 9, 2007

PharmEng Opens $15M Pharmaceutical Manufacturing Facility

  • PharmEng, a consulting and contract manufacturing company, opened a $15 million pharmaceutical manufacturing facility in North Sydney, Nova Scotia.

    The 46,400 sq.ft. facility located on five acres operates under the name of Keata Pharma and includes offices for PharmEng's pharmaceutical consulting division, pilot laboratories for formulation development, equipment for modified-release technology, and rooms with various capabilities such as high shear mixing and container blending all in a control environment that meets all cGMP requirements.

    The facility will have the necessary equipment and approvals to provide formulation development and testing services to manufacture and package products in solid and liquid dosage forms, reports the company. Keata's long-term goal is to develop capabilities in other dosage forms, such as suppositories, topicals, and injectables.

    The facility will initially employ 65 workers and is anticipated to grow to in excess of 150 workers within three years, according to the company. Production is expected to commence in early Q1 of 2008.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »